Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution

References

• Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: Formulation, process and storage considerations. Adv Drug Deliv Rev, 2006;58:1688–713
   PubMed Web of Science ®Google Scholar
• Bakala N'Goma JC, Amara S, Dridi K, Jannin V, Carrière F. Understanding lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. Ther Deliv, 2012;3:105–24
   PubMedGoogle Scholar
• Chakraborty S, Shukla D, Mishra B, Singh S. Lipid -- An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm, 2009;73:1–15
   PubMed Web of Science ®Google Scholar
• Charman WN, Stella V. J. 1992. Lymphatic transport of drugs. Boca Ratón, FL: CRC Press
   Google Scholar
• Chen M. Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective. Adv Drug Deliv Rev, 2008;60:768–77
   PubMed Web of Science ®Google Scholar
• Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm, 2010;74:474–82
   PubMed Web of Science ®Google Scholar
• Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm, 2007;67:96–105
   PubMed Web of Science ®Google Scholar
• Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release, 2008;129:1–10
   PubMed Web of Science ®Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 2011;12:62–76
   PubMed Web of Science ®Google Scholar
• del pozo-Rodríguez A, Solinís MA, Gascón AR, Pedraz JL. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm, 2009;71:181–9
   PubMed Web of Science ®Google Scholar
• European Pharmacopeia. 2007. Dissolution test for solid dosage forms. 7th edn. 2011
   Google Scholar
• Florence AT. Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov Today: Technol, 2005;2:75–81
   PubMedGoogle Scholar
• Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas. Adv Drug Deliv Rev, 2001;50:S69–89
   PubMed Web of Science ®Google Scholar
• Guide for the Care and Use of Laboratory Animals. 2011. Washington, DC: National Academies Press (US)
   Google Scholar
• Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev, 2007;59:667–76
   PubMed Web of Science ®Google Scholar
• Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev, 2008;60:734–46
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing – Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 2007;59:631–44
   PubMed Web of Science ®Google Scholar
• Konan YN, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 2002;233:239–52
   PubMed Web of Science ®Google Scholar
• Krishnaiah YSR. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab, 2010;2:28–36
   Google Scholar
• Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm, 2005;31:319–29
   PubMed Web of Science ®Google Scholar
• Limayem Blouza I, Charcosset C, Sfar S, Fessi H. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm, 2006;325:124–31
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165–96
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicol Pathol, 2008;36:43–8
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev, 2011;63:427–40
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci, 2003;18:113–20
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Müller R. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm, 2008;34:1394–405
   PubMed Web of Science ®Google Scholar
• Müller R, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery -- A review of the state of the art. Eur J Pharm Biopharm, 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm, 2002;242:121–8
   PubMed Web of Science ®Google Scholar
• Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals. Int J Pharm, 2006;317:82–89
   PubMed Web of Science ®Google Scholar
• Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol, 2010;62:1622–36
   PubMed Web of Science ®Google Scholar
• O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility -- The potential impact of lipid-based formulations. Adv Drug Deliv Rev, 2008;60:617–24
   PubMed Web of Science ®Google Scholar
• Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact, 1987;5:273–302
   PubMedGoogle Scholar
• Porter C, Trevaskis N, Charman W. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov, 2007;6:231–48
   PubMed Web of Science ®Google Scholar
• Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev, 2008;60:673–91
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 2006;29:278–87
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliv Rev, 2008;60:625–37
   PubMed Web of Science ®Google Scholar
• Saha GB. 2010. Fundamentals of Nuclear Pharmacy. 6th edn. New York, NY: Springer
   Google Scholar
• Szymendera J, Radwan M. Intestinal absorption of pertechnetate: Calculation by the oral-intravenous plasma activity quotients and inverse convolution method. J Nucl Med, 1974;15:314–16
   PubMed Web of Science ®Google Scholar
• Tarr BD, Yalkowsky SH. Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm Res, 1989;6:40–3
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Müller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) -- Effects of formulation parameters on physicochemical stability. Int J Pharm, 2007;340:198–206
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev, 2008;60:702–16
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. 2001. Rockville: Centre for Drug Evaluation and Research (CDER)
   Google Scholar
• Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces, 2012;95:1–9
   PubMed Web of Science ®Google Scholar
• Williams H, Sassene P, Kleberg K, Bakala N'Goma JC, Calderone M, Jannin V, Igonin A, Partheli A, Marchaud D, Vertommen J, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: Method parameterisation and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci, 2012;101:3360–80
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin J, Kang C, Li J, Zhu Y, Li W, Huang Q, Zhu Z. Biodistribution and toxicity of nanodiamonds in mice after intratracheal instillation. Toxicol Lett, 2010;198:237–43
   PubMed Web of Science ®Google Scholar